Gene Therapy
Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO
Published in Gene Therapy Weekly, May 20th, 2010
Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale. PF-04523655 is a chemically-modified siRNA drug candidate being co-developed by Quark and Pfizer for the treatment of wet age-related macular degeneration (wet-AMD) and diabetic macular edema (DME). PF-04523655 was designed to be resistant to nuclease degradation that can occur during normal cellular uptake processes in the eye without using a specific delivery...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2010-05-20)
More Articles from Gene Therapy Weekly
- Hemic and Immune Systems
Data on hemic and immune systems detailed by researchers at University Medical Center - Stem Cell Research
Data on stem cell research detailed by M. Sioud and co-authors - Enzymes and Coenzymes
Findings from W. Zalewski et al in enzymes and coenzymes reported - Nanoparticles
Findings from Zhejiang University broaden understanding of nanoparticles - Carboxylic Acids
New findings from Yale University in the area of carboxylic acids published - Eicosanoids
New findings in eicosanoids described from University of Munich - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
